Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Semin Liver Dis 2014; 34(02): 215-226
DOI: 10.1055/s-0034-1375961
DOI: 10.1055/s-0034-1375961
DILI and Drug Development: A Regulatory Perspective
Further Information
Publication History
Publication Date:
31 May 2014 (online)
Abstract
The assessment of risk for serious, life-threatening drug-induced liver injury (DILI) associated with a suspect drug, biological agent, or herbal product depends on an iterative analysis of pre- and postmarket datastreams. Because serious cases of idiosyncratic DILI are typically rare, regulatory scientists seek strategies that accurately predict from clinical trial data which study drugs will be likely to cause these events in a large postmarket treatment population, e.g., through the identification of cases that are consistent with Hy's law. This objective is only achievable if rigorous standards in study subject monitoring, data collection and analysis of liver injury cases for causality are followed. In the future, the development of more effective predictive and analytic tools in preclinical and clinical testing will provide a framework to reliably identify new agents that have hepatotoxic profiles as well as those individuals who are susceptible to develop serious DILI.
-
References
- 1 Meadows M. Promoting Safe and Effective Drugs for 100 years. 2006. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/CentennialofFDA/CentennialEditionofFDAConsumer/ucm093787.htm . Accessed September 20, 2013
- 2 Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16 (15-16) 697-703
- 3 Liver Toxicity Knowledge Database (LTKB) Benchmark Dataset. National Center for Toxicological Research. U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ucm226811.htm . Accessed September 20, 2013
- 4 Temple RJ. Welcome to DILI. AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2011. Available at: http://www.aasld.org/meetings/Documents/Hepatotoxicity%20STC/0-1_Temple.pdf . Accessed September 13, 2013
- 5 Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011; 20 (7) 772-777
- 6 Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14 (3-4) 162-167
- 7 Watkins PB, Bloom J, Hunt C. Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials. In: Olson S, Robinson S, Giffin R, , eds. Accelerating the Development of Biomarkers for Drug Safety: Institute of Medicine Workshop Summary. San Diego, CA: Academic Press; 2009. :Chapter 5,42–57
- 8 MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Available at: http://www.fda.gov/safety/MedWatch/default.htm . Accessed September 20, 2013
- 9 Avigan MI. Regulatory perspectives. In: Kaplowitz N, Deleve LD, , eds. Drug-Induced Liver Disease. 3 rd ed. London, UK: Academic Press; 2013: 689-712
- 10 Avigan MI. Finding predictive biomarkers: Can we harmonize across clinical trials? AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2013. Available at: http://www.aasld.org/dili/Documents/2013/4A_1_M_Avigan-n.pdf . Accessed September 20, 2013
- 11 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4 (6) 489-499
- 12 Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011; 8 (4) 202-211
- 13 Aithal GP, Watkins PB, Andrade RJ , et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6) 806-815
- 14 Senior JR, Avigan M. Detection of hepatotoxicity during drug development: practical problems and regulatory measures. In: Andrade RJ, , ed. Hepatotoxicity. Arroyo V, ed. International Hepatology Updates. Barcelona: Permanyer Publications; 2007: 147-166
- 15 Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011; 53 (4) 1377-1387
- 16 Kullack-Ublick GA. Drug-induced cholestatic liver disease. In: Trauner M, Jansen P, , eds. Molecular Pathogenesis of Cholestasis. Austin, TX: Landes Bioscience; 2003
- 17 Kaplowitz N. Drug-induced liver injury, introduction and overview. In: Kaplowitz N, Deleve LD, , eds. Drug-Induced Liver Disease. 3 rd ed. London, UK: Academic Press; 2013: 3-14
- 18 Phenotypes of Drug-Induced Liver Injury. LiverTox. Available at: http://www.livertox.nih.gov/Phenotypes_intro.html . Accessed September 19, 2013
- 19 Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48 (5) 1680-1689
- 20 Olsson R, Korsan-Bengtsen B-M, Korsan-Bengtsen K, Lennartsson J, Waldenström J. Serum aminotransferases after low-dose heparin treatment. Short communication. Acta Med Scand 1978; 204 (3) 229-230
- 21 Harrill AH, Roach J, Fier I , et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 2012; 92 (2) 214-220
- 22 Watkins PB, Kaplowitz N, Slattery JT , et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296 (1) 87-93
- 23 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13) 992-998
- 24 Product label for Zocor (simvastatin). Approved October 6, 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s083lbl.pdf . Accessed September 20, 2013
- 25 Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29 (4) 412-422
- 26 Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41 (4) 690-695
- 27 Hautekeete ML, Horsmans Y, Van Waeyenberge C , et al. HLA association of amoxicillin-clavulanate—induced hepatitis. Gastroenterology 1999; 117 (5) 1181-1186
- 28 O'Donohue J, Oien KA, Donaldson P , et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47 (5) 717-720
- 29 Kindmark A, Jawaid A, Harbron CG , et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8 (3) 186-195
- 30 Singer JB, Lewitzky S, Leroy E , et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42 (8) 711-714
- 31 Daly AK, Donaldson PT, Bhatnagar P , et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41 (7) 816-819
- 32 Hirata K, Takagi H, Yamamoto M , et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8 (1) 29-33
- 33 Spraggs CF, Budde LR, Briley LP , et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29 (6) 667-673
- 34 Avigan MI. Key features of DILI biomarkers we need. AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2012. Available at: http://www.aasld.org/dili/Documents/2012/3A-1_AviganN.pdf . Accessed September 20, 2013
- 35 Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15 (4) 241-243
- 36 Reuben A. Hy's law. Hepatology 2004; 39 (2) 574-578
- 37 Fontana RJ, Seeff LB, Andrade RJ , et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52 (2) 730-742
- 38 Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009; 29 (4) 348-356
- 39 Avigan MI, Bjornsson EI, Pasanen M , et al. Required data elements and best practices for data collection and standardization. Conference Report: Workshop on Liver Safety Assessment in Clinical Drug Development. Drug Saf 2014; ; In Press
- 40 FDA Guidance for Industry. Drug-induced liver injury: Pre-marketing clinical evaluation. July 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf . Accessed September 20, 2013
- 41 Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42 (2) 481-489
- 42 Andrade RJ, Lucena MI, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (2) 512-521
- 43 Rosner B. The binomial distribution. In: Rosner B, , ed. Fundamentals of biostatistics. Belmont, CA: Duxbury Press; 1995: 82-85
- 44 Gelperin K, Guo T, Senior J. A simple tool for finding important cases in a clinical trial. AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2008. Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf . Accessed September 20, 2013
- 45 Watkins PB, Desai M, Berkowitz SD , et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34 (3) 243-252
- 46 Senior J. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: Current status and challenges. Conference report: Workshop on Liver Safety Assessment in Clinical Drug Development. Drug Saf 2014; ; In press
- 47 Senior JR. Hepatic safety of tolvaptan. In: FDA Briefing Document; Center for Drug Evaluation and Research Advisory Committee Meeting Briefing. August 5, 2013:183–208. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM363343.pdf . Accessed September 28, 2013
- 48 Torres VE, Chapman AB, Devuyst O , et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367 (25) 2407-2418
- 49 Seeff L. Drug-induced liver injury in persons with pre-existing liver disease. AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2013. Available at: http://www.aasld.org/dili/Documents/2013/2A_4_L_Seeff-n.pdf . Accessed September 20, 2013
- 50 Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins P. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Conference report: Workshop on Liver Safety Assessment in Clinical Drug Development. Drug Saf 2014; ; In Press
- 51 Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15 (4) 213-220
- 52 Knowler WC, Hamman RF, Edelstein SL , et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54 (4) 1150-1156
- 53 Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98 (1) 175-179
- 54 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129 (1) 36-38
- 55 Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114 (4) 299-306
- 56 Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130 (2) 163-164
- 57 He R. Clinical review of Exanta (ximelagatran) tablets. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_04_FDA-Backgrounder-MOR-180.pdf . Accessed September 20, 2013
- 58 Avigan M. Case Study: Ximelagatran hepatotoxicity. AASLD-FDA Annual Meeting on Drug-Induced Liver Injury. January 2005. Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/.../ucm080355.ppt . Accessed September 20, 2013
- 59 EMEA press release. AstraZeneca withdraws its application for ximelagatran 36-mg film-coated tablets. London, February 16, 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/02/WC500074073.pdf . Accessed September 20, 2013
- 60 Klickstein L. Therapeutic Arthritis Research and Gastrointestinal Events Trial (TARGET). AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2012. Available at: http://www.aasld.org/dili/Documents/2012/2A-2_KlicksteinN.pdf . Accessed September 20, 2013
- 61 Lumiracoxib (Prexige). Urgent advice regarding management of patients. Australian Government, Therapeutic Goods Administration. August 13, 2007. Available at: http://www.tga.gov.au/safety/alerts-medicine-lumiracoxib-070813.htm . Accessed September 20, 2013
- 62 Brinker AD, Lyndly J, Tonning J, Moeny D, Levine JG, Avigan MI. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf 2013; 36 (12) 1169-1178
- 63 European Medicines Agency. Guideline on the processing of renewals in the centralised procedure. June 22, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/03/WC500124501.pdf . Accessed September 20, 2013
- 64 European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. July 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500003981.pdf . Accessed September 20, 2013
- 65 FDA Draft Guidance for Industry. Expedited Programs for Serious Conditions – Drugs and Biologics. June 2013. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf . Accessed September 20, 2013
- 66 Ipilimumab FDA-approved product label. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf . Accessed September 20, 2013
- 67 Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12 (7) 864-872
- 68 Hoos A, Ibrahim R, Korman A , et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37 (5) 533-546
- 69 Hodi FS, O'Day SJ, McDermott DF , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8) 711-723
- 70 Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J 2008; 10 (1) 35-41
- 71 Weaver J, Grenade LL, Kwon H, Avigan M. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA). Dermatol Ther 2009; 22 (3) 204-215
- 72 Ahmad SR, Goetsch RA, Marks NS. Spontaneous Reporting in the United States. In: Strom BL, , ed. Pharmacoepidemiology. 4th ed. West Sussex, England: John Wiley & Sons, Ltd.; 2005: 135-159
- 73 Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005; 33 (1) 155-164
- 74 Fontana RJ, Watkins PB, Bonkovsky HL , et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32 (1) 55-68
- 75 de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58 (1) 71-80
- 76 Avigan M. Drug-induced liver injury: Epidemiology and considerations of risk. American Thyroid Association, April 18, 2009. Available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM164456.pdf . Accessed September 22, 2013
- 77 Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System—a national resource for evidence development. N Engl J Med 2011; 364 (6) 498-499
- 78 Robb MA, Racoosin JA, Sherman RE , et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 2012; 21 (21) (Suppl. 01) 9-11
- 79 Agarwal VK, McHutchison JG, Hoofnagle JH ; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8 (5) 463-470
- 80 García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM). Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55 (3) 683-691
- 81 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2) 272-276
- 82 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46 (11) 1323-1330
- 83 Rochon J, Protiva P, Seeff LB , et al; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48 (4) 1175-1183
- 84 Rockey DC, Seeff LB, Rochon J , et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51 (6) 2117-2126
- 85 Freston JW. Use and limitations of the RUCAM. AASLD-FDA Annual meeting on drug-induced liver injury, January 2006. Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm079446.pdf . Accessed September 20, 2013
- 86 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26 (3) 664-669
- 87 Brinker AD, Wassel RT, Lyndly J , et al. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49 (1) 250-257
- 88 Zapater P, Such J, Pérez-Mateo M, Horga JF. A new Poisson and Bayesian-based method to assign risk and causality in patients with suspected hepatic adverse drug reactions: a report of two new cases of ticlopidine-induced hepatotoxicity. Drug Saf 2002; 25 (10) 735-750
- 89 Lanctôt KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995; 58 (6) 692-698
- 90 Théophile H, André M, Arimone Y, Haramburu F, Miremont-Salamé G, Bégaud B. An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. J Clin Epidemiol 2012; 65 (10) 1069-1077
- 91 Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation—drug induced liver injury prediction system (DILIps). PLOS Comput Biol 2011; 7 (12) e1002310
- 92 FDA Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. March 2005. Available at: http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdf . Accessed September 20, 2013
- 93 Reporting Serious Problems to FDA . Available at: http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm . Accessed September 20, 2013
- 94 LiverTox. Information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to prescription and nonprescription medications, herbals and dietary supplements. Available at: http://www.livertox.nih.gov/ . Accessed September 23, 2013
- 95 FDA's Sentinel Initiative – Ongoing Projects. 11 July 2012. Available at: http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm203500.htm . Accessed September 20, 2013
- 96 Platt R, Carnahan RM, Brown JS , et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl. 01) 1-8
- 97 Stang PE, Ryan PB, Racoosin JA , et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153 (9) 600-606
- 98 Lo Re III V, Haynes K, Goldberg D , et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf 2013; 22 (8) 861-872
- 99 Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?. Pharmacogenomics 2012; 13 (7) 735-738
- 100 FDA Guidance for Industry. Clinical pharmacogenomics: Premarketing evaluation in early phase clinical studies and recommendations for labeling. January 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM337169.pdf . Accessed September 20, 2013
- 101 Watkins PB. Sharing information – asking questions: safety data warehouse? AASLD-FDA Annual Meeting on Drug-Induced Liver Injury, March 2012. Available at: http://www.aasld.org/dili/Documents/2012/3B-5_WatkinsN.pdf . Accessed September 20, 2013
- 102 Food and Drug Administration. Notice. Availability of masked and de-identified non-summary safety and efficacy data; request for comments. Fed Regist 2013;
- 103 European Medicines Agency. Draft for public consultation. Publication and access to clinical-trial data. June 24, 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf . Accessed November 6, 2013
- 104 Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for responsible sharing of clinical trial data. N Engl J Med 2013; 369 (17) 1651-1658
- 105 FDA Draft Guidance for Industry. Pharmacogenomic data submissions. March 2005. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079849.pdf . Accessed September 20, 2013
- 106 FDA Draft Guidance for Industry. Qualification process for drug development tools. October 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf . Accessed September 20, 2013